Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
06 November 2014Website:
http://www.nevro.comNext earnings report:
01 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 21:29:36 GMTDividend
Analysts recommendations
Institutional Ownership
NVRO Latest News
REDWOOD CITY, Calif. , June 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on June 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 56,692 shares of Nevro's common stock to 17 new non-executive employees to induce them to accept employment with Nevro.
REDWOOD CITY, Calif. , June 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:40 am EDT.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on May 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 59,460 shares of Nevro's common stock to twenty-six new non-executive employees to induce them to accept employment with Nevro.
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
- 1(current)
What type of business is Nevro?
Nevro Corp. is a global medical equipment company focused on providing innovative products that improve the quality of life for patients suffering from chronic pain. The company has developed the Senza spinal cord stimulation system, a scientifically based neuromodulation platform for treating chronic pain, and has also launched the latest product platform, Senza Omnia. The company launched Senza in the United States in May 2015, in some European countries since November 2010, and in Australia since August 2011. Currently, Senza is covered by all major insurance companies, and the patented hf10 therapy without sensory disturbances outperforms traditional spinal cord stimulation therapy, with hf10 therapy being nearly twice as successful in treating back pain and 1.5 times more successful in treating leg pain compared to traditional spinal cord stimulation therapy.
What sector is Nevro in?
Nevro is in the Healthcare sector
What industry is Nevro in?
Nevro is in the Medical Devices industry
What country is Nevro from?
Nevro is headquartered in United States
When did Nevro go public?
Nevro initial public offering (IPO) was on 06 November 2014
What is Nevro website?
https://www.nevro.com
Is Nevro in the S&P 500?
No, Nevro is not included in the S&P 500 index
Is Nevro in the NASDAQ 100?
No, Nevro is not included in the NASDAQ 100 index
Is Nevro in the Dow Jones?
No, Nevro is not included in the Dow Jones index
When does Nevro report earnings?
The next expected earnings date for Nevro is 01 August 2024